Entity
  • Abivax

    Created in 2013
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    1,288 10,247
  • Activities

  • Technologies

  • Entity types

  • Location

    Corporate Office, 11 Bd Haussmann 7, 75009 Paris, France

    Paris

    France

  • Employees

    Scale: 51-200

    Estimated: 79

  • SIREN

    799363718
  • Engaged corporates

    8
    5 4
  • Added in Motherbase

    3 years, 7 months ago
Description
  • Value proposition

    Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease.

    Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.

    R&D, Inflammatory Bowel Desease, Biotechnology, Innovation, Ulcerative colitis, and Crohn's disease

  • Original language

    Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease.

    Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.

  • Abivax | Official Website

    Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA.

  • https://www.abivax.com/?lang=fr
Corporate interactions BETA
Corporate TypeTweets Articles
Euronext
Euronext
Finance, Financial Services
Euronext
Finance, Financial Services
Not capitalistic
Partnership
Not event

31 May 2022


BFM Business
BFM Business
Media, Broadcast Media Production and Distribution
BFM Business
Media, Broadcast Media Production and Distribution
Other

24 Oct 2023


Institut Curie
Institut Curie
Health, Hospitals and Health Care
Institut Curie
Health, Hospitals and Health Care
Other

19 Sep 2017


Avolta
Avolta
Finance, Investment Banking
Avolta
Finance, Investment Banking
Other

31 Aug 2022


Nasdaq
Nasdaq
Finance, Financial Services
Nasdaq
Finance, Financial Services
Other

8 Dec 2023


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

13 Jun 2017


Sofinnova Partners
Sofinnova Partners
Financial Services
Sofinnova Partners
Financial Services
Other

18 Nov 2023


CNRS
CNRS
Research, Research Services
CNRS
Research, Research Services
Not capitalistic
Not partnership
Event

12 May 2017


Similar entities
Loading...
Loading...
Social network dynamics